Craig S Siegel

This inventor holds 42 USPTO granted patents and 7 published patent applications and 16 EPO patents, primarily in Glucosylceramide Inhibitors. Top assignees: Genzyme Corporation, University of Michigan, University of Iowa Research Foundation. Active years: 1981-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Craig S Siegel. Retrieved from https://idiyas.com/inventor/craig-s-siegel

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 42 (Patent Applications = 7)

% Patents Active = 81.0

EPO Patents = 16 (Patent Applications = 14)

Average Co-Inventor Count = 4.1

ph-index = 18

Forward Citations = 964(Granted Patents)

Location History:

Ringwood, NJ (US) (1981)
Woburn, MA (US) (1997 - 2022)

Company Filing History:

University of Michigan

patents

1 out of 925

University of Iowa Research Foundation

patents

4. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1981-2025

Loading Chart...

Areas of Expertise:

Glucosylceramide Synthase

Cationic Amphiphiles

Intracellular Delivery

Therapeutic Molecules

Gene Therapy

Cell Transfections

UDP-Glucose

Amino Ceramide

Synthesis

Targeting

Cationic Complexes

42 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12465586 - Inhibitors of glucosylceramide synthase (2025-11-11),

2. 11458119 - Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase (2022-10-04),

3. 10954230 - Method of preparing glucosylceramide synthase inhibitors (2021-03-23),

4. 10604518 - Method of preparing glucosylceramide synthase inhibitors (2020-03-31),

5. 10065949 - Method of preparing glucosylceramide synthase inhibitors (2018-09-04),

6. 9745294 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2017-08-29),

7. 9744153 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2017-08-29),

8. 9682975 - Method of preparing glucosylceramide synthase inhibitors (2017-06-20),

9. 9546161 - [object Object] (2017-01-17),

10. 9518049 - Salt forms of (S)-quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate (2016-12-13),

11. 9272996 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2016-03-01),

12. 8940776 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2015-01-27),

13. 8779163 - [object Object] (2014-07-15),

14. 8309593 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2012-11-13),

15. 8304447 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors (2012-11-06),

Title: Craig S Siegel: Innovator in Pharmaceutical Applications

Introduction

Craig S Siegel is a prominent inventor based in Woburn, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors for glucosylceramide synthase. With a total of 42 patents to his name, Siegel's work has had a substantial impact on medical research and treatment options.

Latest Patents

Among his latest patents, Siegel has developed inhibitors of glucosylceramide synthase, specifically the hemitartrate salt of a compound represented by a unique structural formula. This compound may be utilized in various pharmaceutical applications. The particular single crystalline forms of this hemitartrate are characterized by a range of properties and physical measurements. Additionally, he has outlined methods for producing crystalline forms of this compound and its application in inhibiting glucosylceramide synthase or lowering glycosphingolipid concentrations in subjects to treat several diseases. His patents also describe pharmaceutical compositions that incorporate these innovative compounds.

Career Highlights

Craig S Siegel has worked with notable organizations such as Genzyme Corporation and the University of Michigan. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

Some of his notable coworkers include David J Harris and Edward R Lee. Their collaborative efforts have further advanced the research and development of pharmaceutical innovations.

Conclusion

Craig S Siegel's contributions to the field of pharmaceuticals through his numerous patents and collaborations highlight his role as a key innovator. His work continues to influence the development of treatments for various diseases, showcasing the importance of innovation in healthcare.

Profile summary based on public USPTO records.